Sign in Subscribe
Communicable diseases

Millenia Hope Initiates Second Trial for Malaria Treatment

Strategic Insights

— 1 min read

Millenia Hope Inc., a biotechnology corporation, has initiated a second trial for its malaria treatment, MMH Malarex, in the Republic of Central Africa (RCA). The trial, which will be conducted in three major cities, aims to study the effectiveness of MMH Malarex in children with noncomplicated malaria, who have no signs of malnutrition or other diseases such as HIV and hepatitis. This latest trial follows the company's recent success with three efficacy trials, which demonstrated the treatment's effectiveness in reducing fever and parasite density in patients with malaria.

Key Takeaways:

  • The new Millenia Hope trial involves 360 pediatric patients with noncomplicated malaria, who have no signs of malnutrition or other diseases, and will be conducted in three major cities in the Republic of Central Africa.
  • The trial is being closely monitored by the World Health Organization (WHO), UNICEF, and the Pasteur Institute, France, which have approved the protocol.
  • Previous efficacy trials have demonstrated the effectiveness of MMH Malarex in reducing fever and parasite density in patients with malaria, with 5-day treatment significantly decreasing parasite density and anemia in all patients.
  • Millenia Hope has been engaged in the fight against malaria for over 8 years and has permission to sell its products in 16 countries, with three more to come.
  • The company aims to sell 300,000 treatments in two major markets this year.

Statistics:

  • 360 pediatric patients will be involved in the new trial.
  • The trial will be conducted in three major cities in the Republic of Central Africa.
  • MMH Malarex has demonstrated a major impact on drug-resistant strains of malaria.
  • The treatment reduces fever in the majority of patients within 3-4 days and significantly decreases parasite density per ul of blood from as high as 50,000 per ul to 200 in 5 days.
  • 100% of patients showed a decrease in parasite density to zero within 7 days, and the disease-associated anemia improved significantly during the 14-day follow-up period.
  • Malaria claims nearly 3 million lives annually, with a global market estimated at $10 billion US.

Sources:

  • Millenia Hope Inc.
  • World Health Organization (WHO)
  • UNICEF
  • Pasteur Institute, France
  • Health & Medicine Week
  • Copyright 2005, Health & Medicine Week via NewsRx.com

Read more